Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Axitinib (Primary)
- Indications Paraganglioma; Phaeochromocytoma
- Focus Therapeutic Use
- 16 Dec 2020 Status changed from active, no longer recruiting to completed.
- 06 Apr 2019 Planned End Date changed from 1 Dec 2019 to 1 Dec 2020.
- 05 May 2018 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.